lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmológicos - lucentis está indicado en adultos para:el tratamiento de glaucoma (húmedo) relacionada con la edad degeneración macular (amd)el tratamiento de la discapacidad visual, debido a la neovascularización coroidea (nvc)el tratamiento de la discapacidad visual debido a edema macular diabético (dme)el tratamiento de la discapacidad visual, debido a que el edema macular secundario a la oclusión venosa retiniana (rama rvo o central rvo).
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmológicos - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
lucentis 10 mg/ml solucion inyectable
novartis biosciences peru s.a. - droguerÍa - ranibizumab; - solucion inyectable - por mililitro 10.00 mg - - ranibizumab
lucentis 10mg/ml solucion inyectable
novartis biosciences peru s.a. - ranibizumab; - solucion inyectable - por jeringa prellenada ml; ranibizumab 1.650000 mg; - ranibizumab
lucentis solución intravítrea
scienza uruguay - solución intravítrea - ranibizumab 10 mg/ml inyectable intraocular
ipique
rotterdam biologics b.v. - bevacizumab - degeneración macular húmeda - oftalmológicos - treatment of neovascular (wet) age-related macular degeneration (amd).
lucentis 10 mg/ml solución para inyección
novartis pharma a.g. [ch] switzerland - ranibizumab 10.0 mg - solucion inyectable - cada ml de soluciÓn para inyecciÓn contiene: ranibizumab??????????????????????????????? 10 mg
lucentis 10 mg/ml 1 xeringa precarregada